Patient stratification using point of care biomarkers in dry eye disease

With changes in lifestyle, such as the increasing use of digital screens and rising demand for refractive surgery, dry eye disease has become increasingly prevalent in recent times. While we are equipped with a number of diagnostic modalities and a myriad of treatment forms, ranging from topical medication to procedural therapies, the condition remains an enigma in terms of varied patient satisfaction. An understanding of the molecular basis of a disease may open up new avenues in the customization of its treatment. We attempt to simplify this in the form of a stepwise protocol to incorporate biomarker assays in dry eye management.

[1]  R. Shetty,et al.  Clinical and Molecular Outcomes After Combined Intense Pulsed Light Therapy With Low-Level Light Therapy in Recalcitrant Evaporative Dry Eye Disease With Meibomian Gland Dysfunction , 2021, Cornea.

[2]  S. Chauhan,et al.  A new non-human primate model of desiccating stress-induced dry eye disease , 2021, Scientific Reports.

[3]  A. Acera,et al.  Quantification of a panel for dry-eye protein biomarkers in tears: A comparative pilot study using standard ELISA and customized microarrays , 2021, Molecular vision.

[4]  R. Shetty,et al.  Tear Fluid Angiogenic Factors: Potential Noninvasive Biomarkers for Retinopathy of Prematurity Screening in Preterm Infants , 2021, Investigative ophthalmology & visual science.

[5]  Krati Gupta,et al.  Algorithmic approach to diagnosis and management of post-refractive surgery dry eye disease. , 2020, Indian journal of ophthalmology.

[6]  R. Mohan,et al.  Identification of novel predictive factors for post surgical corneal haze , 2019, Scientific Reports.

[7]  R. Shetty,et al.  Trehalose augments autophagy to mitigate stress induced inflammation in human corneal cells. , 2019, The ocular surface.

[8]  L. Tong,et al.  Role of tear film biomarkers in the diagnosis and management of dry eye disease , 2019, Taiwan journal of ophthalmology.

[9]  C. Jayadev,et al.  Altered tear inflammatory profile in Indian keratoconus patients - The 2015 Col Rangachari Award paper , 2017, Indian journal of ophthalmology.

[10]  P. Tu,et al.  Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction. , 2017, American journal of ophthalmology.

[11]  P. Asbell,et al.  TFOS DEWS II Clinical Trial Design Report. , 2017, The ocular surface.

[12]  S. Stinnett,et al.  Effect of thermal pulsation treatment on tear film parameters in dry eye disease patients , 2017, Clinical ophthalmology.

[13]  P. Asbell,et al.  The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research , 2017, Investigative ophthalmology & visual science.

[14]  S. Pflugfelder,et al.  Matrix metalloproteinase-9 in the pathophysiology and diagnosis of dry eye syndrome , 2017 .

[15]  J. Mehta,et al.  Advances and Clinical Applications of Anterior Segment Imaging Techniques , 2016, Journal of ophthalmology.

[16]  A. Kampik,et al.  Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. , 2016, Ophthalmology.

[17]  D. Paton Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease. , 2016, Drugs of today.

[18]  A. Galor,et al.  The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye. , 2016, The ocular surface.

[19]  R. Beuerman,et al.  Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. , 2015, Investigative ophthalmology & visual science.

[20]  E. Messmer The pathophysiology, diagnosis, and treatment of dry eye disease. , 2015, Deutsches Arzteblatt international.

[21]  S. Tauber,et al.  Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. , 2013, JAMA ophthalmology.